Rinvoq is manufactured by AbbVie [1].
What is Rinvoq used for?
Rinvoq is a Janus kinase (JAK) inhibitor approved for treating several inflammatory conditions. These include moderate to severely active rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and ulcerative colitis [2]. It is also indicated for Crohn's disease [3].
How does Rinvoq work?
Rinvoq works by blocking the activity of Janus kinases (JAKs), a group of enzymes involved in the signaling pathways of certain immune cells [4]. By inhibiting JAKs, Rinvoq helps to reduce inflammation and suppress the immune system's overactivity, which is characteristic of autoimmune and inflammatory diseases [4].
When did AbbVie's Rinvoq get approved?
Rinvoq received its initial FDA approval in August 2019 for treating rheumatoid arthritis [5]. Subsequent approvals have expanded its use to other indications.
What are the potential side effects of Rinvoq?
Like other JAK inhibitors, Rinvoq carries a risk of serious side effects, including infections, blood clots, heart attack, stroke, and certain cancers [2]. Patients are advised to discuss these risks with their healthcare provider [2].
How does Rinvoq compare to other AbbVie drugs?
AbbVie also produces Humira, a TNF inhibitor, which is also used to treat various inflammatory conditions [6]. While both drugs target inflammation, they do so through different mechanisms [7]. Rinvoq is a JAK inhibitor, whereas Humira is a biologic that blocks Tumor Necrosis Factor-alpha [7].
What is the patent situation for Rinvoq?
Information regarding the specific patent expiry dates for Rinvoq can be found on DrugPatentWatch.com [8]. Patents for pharmaceuticals are crucial for protecting the manufacturer's investment in research and development, typically granting market exclusivity for a set period [8].
What are the alternatives to Rinvoq?
Treatment options for the conditions Rinvoq treats vary widely and depend on the specific disease, severity, and individual patient factors [9]. These can include other classes of medications such as TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, and other JAK inhibitors, as well as traditional disease-modifying antirheumatic drugs (DMARDs) [9].
Sources
1. "AbbVie Inc. (ABBV) Company Profile." Yahoo Finance. https://finance.yahoo.com/quote/ABBV/profile
2. "Rinvoq (upadacitinib)." U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/rinvoq-upadacitinib
3. "Rinvoq FDA Approval History." Drugs.com. https://www.drugs.com/history/rinvoq.html
4. "Upadacitinib." National Institutes of Health (NIH) - DailyMed. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=2e7f7849-4643-47f5-8361-5f271e624973
5. "FDA approves Rinvoq (upadacitinib) for moderate to severe rheumatoid arthritis." AbbVie. (August 16, 2019). https://news.abbvie.com/news/press-releases/fda-approves-rinvoq-upadacitinib-for-moderate-to-severe-rheumatoid-arthritis.htm
6. "Humira (adalimumab)." U.S. Food and Drug Administration. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/humira-adalimumab
7. "AbbVie's Rinvoq (upadacitinib) vs. AbbVie's Humira (adalimumab)." DrugPatentWatch. https://www.drugpatentwatch.com/comparisons/rinvoq-vs-humira
8. DrugPatentWatch.com. https://www.drugpatentwatch.com/
9. "Rheumatoid Arthritis Treatments." Mayo Clinic. https://www.mayoclinic.org/diseases-conditions/rheumatoid-arthritis/diagnosis-treatment/drc-20353090